Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427330 | 1.00 | GBA1 (0.47) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL2569369 | 0.90 | HSD11B1 (0.58) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL2569370 | 0.90 | HSD11B1 (0.58) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL3710748 | 0.88 | HSD11B1 (0.53) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL3710751 | 0.88 | HSD11B1 (0.53) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL3713499 | 0.87 | HSD11B1 (0.52) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL3713502 | 0.87 | HSD11B1 (0.52) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL13015330 | 0.84 | GBA1 (0.46) | GBA1HSD11B1CNR2CNR1KDM4E | |
| SCHEMBL9105684 | 0.80 | HSD11B1 (0.49) | GBA1HSD11B1CNR2CNR1GRM2 | |
| SCHEMBL9105680 | 0.80 | HSD11B1 (0.49) | GBA1HSD11B1CNR2CNR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | GBA1 1744/4885HSD11B1 3407/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.